Response gene to complement 32 (RGC-32) is a cell cycle regulator involved in the proliferation, differentiation and migration of cells and has also been implicated in angiogenesis. Here we show that RGC-32 expression in macrophages is induced by IL-4 and reduced by LPS, indicating a link between RGC-32 expression and M2 polarization. We demonstrated that the increased expression of RGC-32 is characteristic of alternatively activated macrophages, in which this protein suppresses the production of pro-inflammatory cytokine IL-6 and promotes the production of the anti-inflammatory mediator TGF-b. Consistent with in vitro data, tumor-associated macrophages (TAMs) express high levels of RGC-32, and this expression is induced by tumor-derived ascitic fluid in an M-CSF-and/or IL-4-dependent manner. Collectively, these results establish RGC-32 as a marker for M2 macrophage polarization and indicate that this protein is a potential target for cancer immunotherapy, targeting tumor-associated macrophages.
INTRODUCTION
Macrophages play indispensable roles in the innate and adaptive immune response to pathogens and tissue homeostasis. 1, 2 Peripheral blood monocytes originally derived from CD34 1 myeloid progenitor cells in the bone marrow circulate in the bloodstream and migrate into tissues or body cavities to complete differentiation into resident macrophages through the coordinated expression of numerous genes. In response to specific requirements, macrophages express specialized and polarized functional properties. 3 Mirroring the Th1/Th2 nomenclature, macrophages are divided schematically into two main classes. 4 Classically activated M1 macrophages are induced by LPS and IFN-c. These effector cells mediate resistance against intracellular parasites and tumors by producing pro-inflammatory cytokines, such as IL-6, TNF-a and IL-1b. In contrast, M2 macrophages are alternatively activated by distinct stimuli and can be subdivided into three subgroups: M2a, M2b and M2c. M2a macrophages are elicited by IL-4 or IL-13, and M2b macrophages are polarized by immune complexes, TLRs and IL-1Ra. Finally, M2c macrophages are stimulated by IL-10, TGF-b and glucocorticoids. 5, 6 These cells play an important role in tumor progression, tissue repair and remodeling. 7, 8 Tumor-associated macrophages (TAMs) derived from circulating monocytes represent a distinct type of M2 macrophage. 9 TAMs carry out several M2-associated pro-tumoral functions, including the promotion of tumor cell survival, matrix remodeling and the suppression of adaptive immunity. 10, 11 Thus, TAMs represent a promising and effective target for cancer therapy. 12 The heterogeneous tumor microenvironment differentially influences tumor-associated macrophages, suggesting that it will be necessary to identify common TAM targets for the synthesis of new therapeutic molecules. Therefore, the best target would be a protein that is expressed or overexpressed only in TAMs and not in the resident macrophages of normal tissues or in M1 macrophages. 13 Response gene to complement 32 (RGC-32) primarily acts as a cell cycle regulator and plays an important role in cell proliferation. This protein forms complexes with cyclin-dependent kinase p34CDC2 to enhance kinase activity and induce Sphase entry and mitosis. 14, 15 Moreover, RGC-32 promotes cell migration, inhibits angiogenesis and induces smooth muscle cell differentiation. [16] [17] [18] [19] Interestingly, RGC-32 is abnormally expressed in the peripheral blood mononuclear cells of patients with hyper-immunoglobulin E syndrome and multiple sclerosis. 20, 21 Little is known about the role of RGC-32 in immunity. In the present study, we show that RGC-32 is expressed at high levels in M2 macrophages and TAMs and that tumors induce RGC-32 expression in an M-CSF-and/or IL-4-dependent manner. Improved understanding of the impact of RGC-32 on macrophage functions has the potential to help in the development of new RGC-32-based antitumor strategies.
MATERIALS AND METHODS
Cytokines and reagents M-CSF, IFN-c and IL-4 were purchased from R&D Systems (Minneapolis, MN, USA) and used at 100, 20 and 20 ng/ml, respectively. LPS and phorbol 12-myristate 13-acetate (PMA) were obtained from Sigma (Sigma-Aldrich, St. Louis, MO, USA). Monoclonal anti-human M-CSF and anti-IL-4 blocking and isotype-matched antibodies (Abs) were obtained from R&D Systems (R&D Systems, Abingdon, UK), and both were used at 2.5 mg/ml. The phosphoinositide 3-kinase (PI3K) inhibitor LY294002 was purchased from Cell Signaling Technology (Cell Signaling Technology, Danvers, MA, USA) and used at 10 mM/ml.
Cell culture and experimental treatments
To generate PMA-treated macrophages, 1310 6 THP-1 cells were seeded into complete growth medium supplemented with 100 ng/ml PMA for 48 h. To generate M1-polarized THP-1 macrophages, THP-1 cells were cultured with 100 ng/ml PMA for 6 h and then treated with PMA plus 100 ng/ml LPS and 20 ng/mL IFN-c for 42 h. To generate M2-polarized THP-1 macrophages, THP-1 cells were cultured with 100 ng/ml PMA for 6 h and then treated with PMA plus 20 ng/ml IL-4 for 42 h. 22 Human peripheral blood mononuclear cells were isolated from leukocyte-enriched buffy coats from healthy donors using density gradient centrifugation and were positively selected by MACS CD14 microbeads (Miltenyi Biotec, Auburn, CA, USA). The purity of the isolated CD14 1 monocytes was .98%, as determined by flow cytometry. Monocytes were differentiated into macrophages (M0) in RPMI using 10% FBS containing 100 ng/ml human rhM-CSF for 7 days. M1 and M2 macrophages were obtained by culturing M0 cells for an additional 48 h with 100 ng/ml LPS containing 20 ng/ml IFN-c (for M1 polarization) or 20 ng/ml IL-4 (for M2 polarization), respectively. 23 Human TAMs were obtained from the ascetic fluid of colon adenocarcinoma as previously described.
24 CD14
1 macrophages were isolated through Ficoll gradient cell separation and subsequent magnetic cell sorting using CD14 microbeads. Informed consent was obtained from all patients, and the study protocol was approved by the Ethics Review Board of Qingdao Central Hospital. For experiments using signaling kinase inhibitors, THP-1 cells were pre-incubated with the PI3K inhibitor LY294002 for 60 min. Subsequently, THP-1 cells were differentiated into macrophages.
RNA interference
Transient transfection with siRNA against human RGC-32 (cat. # sc-106499) or two negative siRNA controls (cat. # sc-37007 and sc-44230) was performed using HiPerFect Transfection Reagent (Qiagen, Milano, Italy) according to the manufacturer's instructions. Briefly, a suspension of THP-1 cells (2310 6 /ml) was diluted with an equal volume of serum-free RPMI containing HiPerFect Transfection Reagent (30 ml/ml) and scrambled or RGC-32 siRNA (Santa Cruz, CA, USA). After 12 h, the cells were induced to differentiate by the addition of PMA (100 ng/ml). Transfected cells were maintained in culture for 48 h, and subsequently used for the of protein expression.
Retroviral transfection pBMN-GFP and pBMN-GFP-RGC-32 vectors were kind gifts from Dr Jian Li (Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA). Supernatants containing pBMN-GFP or pBMN-GFP-RGC-32 were collected, filtered and subsequently used to infect THP-1 cells as previously described. 16 Cytokine measurement Culture supernatants were collected from PMA-treated THP-1 macrophages and M1/M2-polarized THP-1 macrophages at 48 h. Cytokine levels were measured using TNF-a, IL-1b, IL-6 and TGF-b ELISA kits (R&D Systems), and the assays were conducted according to the manufacturer's instructions. Briefly, microplates were coated with mouse mAbs specific to TNF-a, IL-1b, IL-6 and TGF-b. Standards and samples were added to each well and incubated for 2 h at room temperature. After washing to remove unbound proteins, enzyme-linked polyclonal antibodies specific to TNF-a, IL-1b, IL-6 and TGF-b were added to the wells and incubated for 2 h at room temperature. After washing to remove the unbound antibodyenzyme reagent, the substrate solution was added to the wells and incubated for 30 min at room temperature in the dark. The optical density (450 nm) of each sample was determined using a microplate reader, and the mean concentration of TNF-a, IL-1b, IL-6 and TGF-b was calculated.
Immunofluorescence staining For immunofluorescence analysis, THP-1 cells were seeded onto poly-L-lysine-coated glass coverslips or plated onto glass coverslips prior to treatment with 100 ng/ml PMA for 48 h. The cells were then fixed in 4% formaldehyde in PBS for 15 min and permeabilized using 0.1% Triton X-100 in PBS for 5 min. After preblocking with 5% normal goat serum (Sigma-Aldrich, St Louis, MO, USA) in PBS for 30 min, the cells were incubated with RGC-32 antibody (Santa Cruz Biotechnology), washed with PBS and incubated with TRITC-conjugated secondary antibody for 1 h at 37 uC. DAPI (Dojindo, Kumamoto, Japan) was used for nuclear counterstaining. Between each step, the coverslips were washed three times for 5 min with PBS. The fluorescence was monitored using a 340 Plan Fluor objective on a Nikon Eclipse E600 microscope. Images were acquired using a SPOT camera and adjusted using Adobe Photoshop software.
Quantitative RT-PCR Total RNA from THP-1 and human primary cells was extracted using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA), and the cDNA was synthesized by reverse transcription. Quantitative RT-PCR was performed in duplicate on a LightCycler 2.0 Instrument (Roche Diagnostic, Mannheim, Germany) and analyzed using the comparative 2 2DCt method as previously described. 25 GAPDH was used as an internal control. The primers for RGC-32, TNF-a, IL-1b, IL-6, TGF-b1 and GAPDH are listed in Supplementary Table 1 .
Western blot THP-1 cells were lysed in RIPA buffer containing a protease inhibitor cocktail. Cell lysates were subjected to 12% SDS-PAGE and transferred onto a nitrocellulose membrane. After blocking with TBST (Tris-buffered saline, 0.1% Tween 20) containing 5% non-fat dried milk, the membranes were incubated with the indicated antibodies, including anti-RGC32 (a kind gift from Professor Jian Li, Beth Israel Deaconess Medical Center, Harvard Medical School), anti-b-actin, anti-AKT and anti-pAKT (Cell Signaling Technology, Danvers, MA, USA) overnight at 4 uC, followed by washing with TBST and incubation with HRP anti-mouse or anti-rabbit IgG for 1 h. The protein bands were detected with enhanced chemiluminescence.
Coimmunoprecipitation (Co-IP) assays
Immunoprecipitation was carried out according to previously described methods.
19,26 After treatment with 0 or 100 ng/ml PMA for 48 h, the cells were collected and suspended in Co-IP assay lysis buffer (Pierce, Rockford, USA) on ice for 30 min. Following rapid centrifugation, the resulting supernatants were incubated with IgG and AKT antibodies at 4 uC for 2 h, followed by incubation with 30 ml of a 1 : 1 slurry of protein A/G Plus-agarose at 4 uC overnight. The precipitates were washed four times with Co-IP buffer and resuspended and boiled in SDS loading buffer. Western blotting was performed using an anti-RGC-32 antibody.
Statistical analysis
The statistical analysis was performed using SPSS software version 13.0 (SPSS, Chicago, IL, USA). The data are presented as the mean6s.d. based on triplet experiments. The data were analyze dusing analysis of variance and Student's t-test (twotailed). Statistical significance was considered as P,0.05.
RESULTS

High expression of RGC-32 in M2 macrophages
THP-1 cells can be activated and differentiated into macrophages by PMA, and this model has been used for studies on monocyte/macrophage differentiation. 27, 28 To clarify the role of RGC-32 in macrophages, we initially examined the Figure 1a) . 22 RGC-32 mRNA expression was considerably higher in PMA-treated and M2-polarized THP-1 macrophages than in M1-polarized THP-1 macrophages (Figure 1d) . Consistent with RGC-32 mRNA expression, RGC-32 protein was increased in PMA-treated and M2-polarized THP-1 macrophages (Figure 1e ). To further analyze RGC-32 mRNA expression in human primary cells, M1 and M2 macrophages were generated as described in the section on 'Materials and methods'. As expected, the results indicated that RGC-32 was expressed at high levels in M2 macrophages (Supplementary Figure 1b) . These results suggest that there is a regulatory mechanism for RGC-32 expression during macrophage polarization.
LPS and IL-4 modulated RGC-32 expression during macrophage polarization
Four different doses of LPS or IFN-c in combination with a standard dose of the other cytokine counterpart were applied to identify the contributions of these cytokines to the regulation of RGC-32 expression. As shown in Figure 2b , LPS significantly decreased RGC-32 mRNA expression in a dose-dependent manner, whereas IFN-c alone did not show any effect (Figure 2a ). In addition, the results also showed that RGC-32 mRNA expression was dependent on the dose of IL-4 in PMAand IL-4-treated THP-1 cells (Figure 2c) . Therefore, these results suggest that LPS and IL-4, but not IFN-c, influence the expression of RGC-32 during macrophage polarization.
RGC-32 modulated cytokine production in macrophages M2-polarized THP-1 macrophages are generally characterized by low production of pro-inflammatory cytokines (IL-6, TNF-a and IL-1b) and high production of TGF-b, in contrast to the pattern seen in M1-polarized THP-1 macrophages. 6, 22 Based on differences in RGC-32 expression in M1 and M2 macrophages, we next investigated whether RGC-32 influences the production of inflammatory cytokines. THP-1 cells were transfected with control or RGC-32 siRNA before being differentiated with PMA for 48 h. RGC-32 expression was effectively reduced using the specific siRNA (Figure 3a) . As shown in Figure 3b , we observed increased production of the key pro-inflammatory cytokine IL-6 and decreased production of the anti-inflammatory cytokine TGF-b in RGC-32-silenced THP-1 macrophages. Complementary experiments in which RGC-32 was overexpressed in THP-1 macrophages resulted in significant inhibition of IL-6 RGC-32 as a marker for M2 macrophages P Zhao et al and an increase in TGF-b (Figure 3c and d) . Together, these results suggest that RGC-32 influences the production of inflammatory cytokines that define macrophage polarization.
A crucial role for the PI3K signaling pathway in RGC-32-mediated IL-6 inhibition PI3K is involved in the positive regulation of IL-6 production. 29 To determine whether the PI3K-mediated pathway is activated in PMA-treated THP-1 cells, we analyzed the phosphorylation of AKT. Western blot analysis showed that AKT phosphorylation gradually increased and peaked at 48 h after treatment with PMA ( Figure 4a ). To determine the mechanisms underlying RGC-32-regulated IL-6 production, we examined the effects of LY294002, a PI3K inhibitor, in RGC-32-silenced macrophages on the upregulation of IL-6 production. The pre-treatment of THP-1 cells with 10 mM LY294002 significantly inhibited PMAinduced IL-6 production ( Figure 4b ). Clearly, the positive effect of RGC-32 silencing on IL-6 production was completely blocked by LY294002 (Figure 4b ). By contrast, the production of IL-1b, TNF-a and TGF-b was not affected in LY294002-pretreated macrophages. In addition, western blot analysis revealed that phosphorylated AKT was upregulated after 48 h in RGC-32-silenced macrophages, whereas the total amount of AKT was unaltered (Figure 4c ). To test whether RGC-32 binds to AKT in THP-1 cells and PMA-treated macrophages, we performed coimmunoprecipitation. As shown in Figure 4d , RGC-32 physically interacts with AKT. Taken together, these results suggest that the PI3K pathway is critically involved in the regulation of IL-6 production by RGC-32 in macrophages.
Increased expression of RGC-32 in TAMs
TAMs originate from blood monocytes recruited to the tumor site by molecules produced by tumors and stromal cells.
CD14
1 TAMs isolated ex vivo from colon adenocarcinoma ascitic fluid expressed higher levels of RGC-32 than did CD14 1 monocytes isolated from human peripheral blood (Figure 5a ). The increased expression of RGC-32 mRNA in TAMs prompted us to examine whether tumor cells influence the expression of this protein in monocytes. As shown in Figure 5b , colon adenocarcinoma ascitic fluid promoted strong upregulation of RGC-32 mRNA, confirming that tumor cells release factors that upregulate RGC-32 expression in monocytes.
Given that RGC-32 expression is induced by M-CSF and IL-4 (Figure 5b) , we tested whether both cytokines contributed to RGC-32 induction in monocytes by tumor-derived ascetic fluids. As shown in Figure 5c , the blocking Abs anti-M-CSF and anti-IL-4 reduced the induction of RGC-32 by colon adenocarcinoma ascitic fluid by 46% and 66%, respectively. However, a synergistic effect was not observed when neutralizing Abs against M-CSF and IL-4 were added to the conditioned medium. Therefore, these results suggest that the increased expression of RGC-32 in TAMs is dependent on tumor-associated M-CSF and IL-4. DISCUSSION RGC-32 has been reported to have pleiotropic effects in diverse cellular processes such as cell proliferation, differentiation and migration. 18, 31, 32 However, a role for RGC-32 in macrophages has not been reported. In the present study, we investigated the expression and regulation of RGC-32 during macrophage polarization and demonstrated that RGC-32 was specifically expressed in M2 macrophages with regulatory or immunosuppressive effector functions.
THP In contrast, LPS negatively regulated RGC-32 expression. Taken together, this evidence indicates that M1 macrophages are devoid of RGC-32 expression, whereas RGC-32 is specific to M2 macrophages, which have anti-inflammatory and regulatory properties. Consistent with the presence of RGC-32 in M2 macrophages, this protein has been detected in CD68 1 macrophages in multiple sclerosis plaques, and the expression of this cell marker is regulated by TGF-b. 21 Therefore, RGC-32 expression marks a wider range of alternatively activated macrophages.
Macrophages are the primary source of pro-and antiinflammatory cytokines, such as IL-6, TNF-a, IL-1b and TGF-b. 33, 34 In the present study, we investigated whether RGC-32 expression in macrophages influenced the expression of inflammatory cytokines. As expected, increased RGC-32 expression in macrophages significantly inhibited the expression of IL-6 and increased the expression of TGF-b, suggesting that RGC-32 influences macrophage polarization by inducing an IL-6 low TGF-b high cytokine profile. The induction of IL-6 by LPS, IL-1b and lysophosphatidic acid is PI3k-dependent. 29, 35 In the present study, we provided evidence that the induction of IL-6 production in PMA-treated THP-1 macrophages was dependent on PI3K activation (Figure 5b) . Interestingly, we observed that the increased production of IL-6 in RGC-32-silenced macrophages was inhibited by a PI3K inhibitor (Figure 5b ), whereas the production of TGF-b was not altered. Silencing of RGC-32 stimulated a significant increase in AKT phosphorylation, demonstrating that RGC-32 negatively regulated the PI3K pathway (Figure 5c Figure 4 PI3K signaling is important for the RGC-32-mediated induction of IL-6 production. (a) THP-1 cells were exposed to 100 ng/ml PMA for the indicated times. Whole-cell lysates were prepared and subjected to western blot analysis to detect phosphorylated Akt. (b) RGC-32-silenced or control THP-1 cells were treated with LY294002 for 1 h prior to further stimulation with PMA. After 48 h, the production of IL-1b, IL-6, TNF-a and TGF-b in the cell-free supernatants was assayed by ELISA. (c) RGC-32-silenced or control THP-1 cells were exposed to PMA for 48 h. Whole-cell lysates were subjected to western blot analysis to detect phosphorylated Akt. (d) RGC-32 physically interacts with AKT in THP-1 cells and PMAtreated macrophages. THP-1 cells were treated with 0 or 100 ng/ml PMA for 48 h, and subsequently coimmunoprecipitation was performed. Control IgG and AKT antibodies were used for coimmunoprecipitation, and anti-RGC-32 was used for immunoblotting. *P,0.05, **P,0.01. PI3K, phosphoinositide 3-kinase; PMA, phorbol 12-myristate 13-acetate; RGC-32, response gene to complement 32. and PMA-treated macrophages. These results are in contrast with previously reported data on the RGC-32-mediated activation of AKT in endothelial cells. 36 In addition, An et al. 16 reported that RGC-32 had no significant effect on the phosphorylation of Akt in human umbilical vein endothelial cells. 16 The disparities among these reports might reflect differences in RGC-32 functions in different cell types. Thus, these data suggest that RGC-32 can modulate IL-6 production through negative regulation of the PI3K pathway. When circulating monocytes are recruited to tumor sites, they are surrounded by signals (such as M-CSF and IL-13) that promote their differentiation to macrophages and to other cells that are needed by the tumors (IL-4, IL-10 and TGF-b). 13, 37 We observed that TAMs express higher levels of RGC-32 than do circulating monocytes, suggesting that tumor-derived cytokines modulate RGC-32 expression in macrophage precursors or infiltrating macrophages. These results indicated that M-CSF induces RGC-32 mRNA expression in monocytes and is the key cytokine for RGC-32 acquisition during the differentiation of monocytes into macrophages. Tumor-derived IL-4, which induces macrophage polarization, further enhances RGC-32 expression in macrophages. Therefore, these data, in part, support the idea that increased RGC-32 mRNA expression in TAMs is induced by tumor-derived M-CSF and IL-4.
In conclusion, these results establish RGC-32 as a molecule that marks macrophages that have been polarized by tumor cells. However, whether the acquisition of RGC-32 expression in TAMs is detrimental to or favors tumor cell growth should be further investigated. Accordingly, RGC-32 might constitute a potential target for antitumor strategies aimed at eliminating tumor-polarized myeloid cells. 
